- Home
- WETO vs EPIX Comparison
WETO vs EPIX Comparison
Compare WETO & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETO
- EPIX
- Stock Information
- Founded
- WETO 2019
- EPIX 2009
- Country
- WETO China
- EPIX Canada
- Employees
- WETO N/A
- EPIX N/A
- Industry
- WETO
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- WETO
- EPIX Health Care
- Exchange
- WETO NYSE
- EPIX Nasdaq
- Market Cap
- WETO 88.0M
- EPIX 75.9M
- IPO Year
- WETO 2025
- EPIX N/A
- Fundamental
- Price
- WETO $1.85
- EPIX $1.72
- Analyst Decision
- WETO
- EPIX Hold
- Analyst Count
- WETO 0
- EPIX 3
- Target Price
- WETO N/A
- EPIX $2.00
- AVG Volume (30 Days)
- WETO 2.3M
- EPIX 53.1K
- Earning Date
- WETO 01-01-0001
- EPIX 08-04-2025
- Dividend Yield
- WETO N/A
- EPIX N/A
- EPS Growth
- WETO N/A
- EPIX N/A
- EPS
- WETO N/A
- EPIX N/A
- Revenue
- WETO $5,350,773.00
- EPIX N/A
- Revenue This Year
- WETO N/A
- EPIX N/A
- Revenue Next Year
- WETO N/A
- EPIX N/A
- P/E Ratio
- WETO N/A
- EPIX N/A
- Revenue Growth
- WETO N/A
- EPIX N/A
- 52 Week Low
- WETO $1.50
- EPIX $1.40
- 52 Week High
- WETO $4.30
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- WETO N/A
- EPIX 51.31
- Support Level
- WETO N/A
- EPIX $1.68
- Resistance Level
- WETO N/A
- EPIX $1.75
- Average True Range (ATR)
- WETO 0.00
- EPIX 0.04
- MACD
- WETO 0.00
- EPIX 0.00
- Stochastic Oscillator
- WETO 0.00
- EPIX 62.50
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.